Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has been shown to be safe and effective in children as young as six. The Danish pharmaceutical giant has experienced significant stock growth in recent years, driven by surging demand for […]
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a second brand of Finerenone in India. This move is set to revolutionize the treatment landscape for chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Finerenone: A Game-Changer […]
Global pharmaceutical leader, Lupin Limited, announced its significant achievement of receiving tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets, both 100 mg and 300 mg. This approval allows Lupin to market a generic equivalent of Invokana Tablets, manufactured by Janssen Pharmaceuticals, […]
Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets in three dosages: 25 mg, 50 mg, and 100 mg. What is ZITUVIO? Containing the active ingredient Sitagliptin, ZITUVIO functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It’s specifically designed […]
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada’s esteemed specialty pharmaceutical giant. This collaboration aims at the commercialization of Liraglutide, a sophisticated drug-device formulation. This game-changing combination has been curated for the proficient treatment and management of challenges like Type 2 diabetes and […]
Abbott has wrapped up the previously announced acquisition of Bigfoot Biomedical. The latter which is a Silicon Valley-based front-runner is celebrated for its revolutionary smart insulin management systems, notably enhancing diabetes care for patients worldwide. This acquisition propels Abbott’s standing in the diabetes domain, complementing its dominant FreeStyle Libre suite – a state-of-the-art continuous glucose […]
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in obesity and related co-morbidities treatment. Alongside the acquisition, the two companies have announced a three-year research and development (R&D) collaboration to discover and develop new pharmaceutical solutions for obesity and […]
Sugar Watchers, a burgeoning health brand specializing in Low Glycemic Index (Low GI) staples, has successfully raised INR 3.6 crores in a recent funding round led by ah! Ventures. Notably, the round also saw investments from The Chennai Angels, Mumbai Angels, Keiretsu Forum, Chandigarh Angels, and Sanjiv Rangrass, ex-ITC board member. Sugar Watchers aims to […]
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a clinical-stage biopharmaceutical player founded by Aditum Bio in 2021. This strategic acquisition sets the stage for Lilly to delve deeper into pioneering treatments for cardiometabolic diseases, including obesity. Central to […]